Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma

Transfusion

Volumn 40, Issue 10, 2000, Pages 1203-1206

  Koenigbauer, Ulrike F ^a   Eastlund, Ted ^a   Day, John W ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMARC; AZATHIOPRINE; DETERGENT; ESTROGEN; FIBRINOGEN; HUMAN ALBUMIN; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPID; NEUTRALIZING ANTIBODY; PREDNISONE; PYRIDOSTIGMINE; SOLVENT; THYROXINE; VIRUS DNA;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DNA DETERMINATION; ERYTHEMA INFECTIOSUM; FATIGUE; FEMALE; FIBRINOGEN BLOOD LEVEL; HASHIMOTO DISEASE; HUMAN; MYASTHENIA GRAVIS; PARVOVIRUS; PLASMA TRANSFUSION; PLASMAPHERESIS; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS ENVELOPE; VIRUS INACTIVATION;

ADULT; DETERGENTS; FEMALE; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PLASMA; PLASMA EXCHANGE; SOLVENTS;

EID: 0033792014     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2000.40101203.x     Document Type: Article

References (41)

1. Role of parvovirus B19 in human disease
2. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay
3. Human parvovirus arthropathy
4. Clinical manifestations of human parvovirus B19 in adults
5. The transfusion-associated transmission of parvovirus B19
6. Human parvovirus infection in pregnancy and hydrops fetalis
7. Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease
8. Chronic parvovirus infection in a presumably immunologically healthy woman
9. Experimental parvoviral infection in humans
10. Neuralgic amyotrophy due to parvovirus infection
11. Fibromyalgia and parvovirus infection
12. Polyarteritis nodosa and parvovirus B19 infection
13. Human parvoviruses: Implications for transfusion medicine
14. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates
15. Parvovirus B19 antibodies in patients with haemophilia A
16. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates
17. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs
18. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization
19. Transmission of human parvovirus B19 by coagulation factor concentrates
20. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate
21. Life-threatening human parvovirus B19 infection in immunocompetent haemophilia
22. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate
23. Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: The role of human B19 parvovirus
24. Parvovirus B19 DNA contamination in coagulation factor VIII products
25. Human parvovirus B19 and blood products
26. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates
27. Detection of parvovirus B19 in donated blood: A model system for screening by polymerase chain reaction
28. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: Implications for efficiency and consistency of removal of B19 DNA during manufacture
29. Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction
30. Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient
31. Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion
32. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation
33. Viral safety of blood derivatives by immune neutralization
34. Manifestations and treatment of human parvovirus B19 infection in immunocompromised patients
35. Immune response to B19 parvovirus and an antibody defect in persistent viral infection
36. Possible transmission of parvovirus B 19 from intravenous immune globulin
37. Albumin batches and B19 parvovirus DNA
38. Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products
39. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates
40. Incidence of human parvovirus B19 DNA detection in blood donors
41. Human parvovirus B19: Prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients